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Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy and an X-linked recessive, progressive
muscle wasting disease caused by the absence of a functional dystrophin protein. Dystrophin has a structural role as a
cytoskeletal stabilization protein and protects cells against contraction-induced damage. Dystrophin also serves a
signaling role through mechanotransduction of forces and localization of neuronal nitric oxide synthase (nNOS), which
produces nitric oxide (NO) to facilitate vasorelaxation. In DMD, the signaling defects produce inadequate tissue
perfusion caused by functional ischemia due to a diminished ability to respond to shear stress induced endothelium-
dependent dilation. Additionally, the structural defects seen in DMD render myocytes with an increased susceptibility
to mechanical stress. The combination of both defects is necessary to generate myocyte damage, which induces
successive rounds of myofiber degeneration and regeneration, loss of calcium homeostasis, chronic inflammatory
response, fibrosis, and myonecrosis. In individuals with DMD, these processes inevitably cause loss of ambulation
shortly after the first decade and an abbreviated life with death in the third or fourth decade due to cardio-respiratory
anomalies. There is no known cure for DMD, and although the culpable gene has been identified for more than twenty
years, research on treatments has produced few clinically relevant results. Several recent studies on novel DMD
therapeutics are vascular targeted and focused on attenuating the inherent functional ischemia. One approach improves
vasorelaxation capacity through pharmaceutical inhibition of either phosphodiesterase 5 (PDE5) or angiotensin-
converting enzyme (ACE). Another approach increases the density of the underlying vascular network by inducing
angiogenesis, and this has been accomplished through either direct delivery of vascular endothelial growth factor
(VEGF) or by downregulating the VEGF decoy-receptor type 1 (VEGFR-1 or Flt-1). The pro-angiogenic approaches also
seem to be pro-myogenic and could resolve the age-related decline in satellite cell (SC) quantity seen in mdx models
through expansion of the SC juxtavascular niche. Here we review these four vascular targeted treatment strategies for
DMD and discuss mechanisms, proof of concept, and the potential for clinical relevance associated with each therapy.
Keywords: Duchenne muscular dystrophy, VEGF, Flt-1, Flk-1, Nitric oxide, PDE5 inhibitor, ACE inhibitor, Satellite cell,
Muscle regeneration, Myofiber damageReview
Duchenne muscular dystrophy (DMD) is an X-linked re-
cessive, progressive muscle wasting disease caused by muta-
tions in the DMD gene that lead to absence of a functional
dystrophin protein [1,2]. Both fatal and devastating, DMD
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reproduction in any medium, provided the orand has an annual incidence affecting one in every 3600–
6000 newborn males [3]. Normally, dystrophin serves as
the bridge in the dystrophin-associated glycoprotein com-
plex (DAPC), connecting the cytoskeleton, via attachments
to subsarcolemmal F-actin, to the extracellular matrix
through an association with plasma membrane bound β-
dystroglycan [4]. In the DAPC, dystrophin has a structural
role as a cytoskeletal stabilization protein and protects
cells against contraction-induced damage. Dystrophin also
serves signaling roles, including mechanotransduction of
forces and localization of signaling proteins, such as neu-
ronal nitric oxide synthase (nNOS), which synthesizes ni-
tric oxide (NO) to facilitate vasorelaxation [5-7]. WithoutLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 The two-hit hypothesis for myocyte damage and the
proposed outcome of functional ischemia attenuation in
Duchenne muscular dystrophy (DMD). (A) The combined effects
from functional ischemia due to reduced nitric oxide (NO)-mediated
protection and greater cellular susceptibility to metabolic stress are
necessary to produce the myofiber damage observed in DMD [17].
(B) Attenuating functional ischemia by administering a vascular
targeted treatment can reduce the net-combined effect of both
two-hit factors and consequently curtail myofiber damage.
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the supportive link between the cytoskeleton and the
extracellular matrix becomes destabilized [8]. Despite nor-
mal development, the membrane in dystrophin-deficient
cells is easily damaged. Membrane microlesions facilitate
an influx of calcium ions, which activate proteases to
begin auto-digestion of the musculature sarcoplasm
[9-11]. Macrophages later arrive at the tissue to remove
cellular debris, and satellite cells (SCs) are activated and
proliferate to induce myofiber regeneration. This causes
successive rounds of myofiber degeneration and regener-
ation that is exacerbated by continual membrane damage
and ensuing myonecrosis. In addition, cytokines released
in the process of myonecrosis recruit inflammatory cells,
which release inflammatory cytokines to activate fibro-
blasts that lay down extracellular matrix proteins and lead
to fibrosis [12]. Skeletal muscle regenerative capacity later
diminishes with advancing age and decreasing numbers of
SCs, and muscle tissue is steadily replaced by adipose and
connective tissues [13].
The previously described cellular events manifest them-
selves clinically in a devastating and progressive manner.
Despite continuous contractions by the myocardium, the
skeletal muscles deteriorate first in individuals with DMD,
and most permanently lose ambulatory abilities shortly
after the first decade [14]. Myocardial problems present
later, and clinically relevant cardiomyopathy is seen in 90%
of patients over 18 years old, namely due to the onset of
cardiac fibrosis in addition to rhythm and conduction ab-
normalities [14]. Respiratory problems are also inevitable
due to muscle wasting in the diaphragm and the onset of
scoliosis [14]. Even with improvements in treatment,
notably multidisciplinary care, the combined cardio-
respiratory anomalies mean that most individuals with
DMD die in their third or fourth decade of life [15,16].
Despite knowledge of the responsible gene for over twenty
years, a DMD cure remains to be found, and research on
treatments has produced few clinically relevant results.
Current treatment options, such as corticosteroid admin-
istration, physical therapy, nocturnal ventilation, and sur-
gical interventions aim for symptomatic management and
have been shown to improve lifespan and quality of life
[16]. The clinical utility and feasibility of gene therapy and
cell therapy remain to be elucidated, and other treatment
areas must be sought. Our current, more holistic under-
standing of DMD pathogenesis, especially with more
recent knowledge of the vascular role of dystrophin, im-
plies that vascular-targeted therapies are strong candi-
dates for future investigation. Specifically, attenuating
functional ischemia could reduce myocyte damage, in-
crease tissue perfusion, reduce cardiac workload, and pre-
vent cardiac and skeletal muscle remodeling (Figure 1B).
This review will focus on vascular-targeted treatment
avenues aimed at either improving vasorelaxation capacityor increasing the underlying vascular density in order to
reduce the functional ischemia and improve the DMD
phenotype.
Defect of nitric oxide-mediated vasodilation contributes
to Duchenne muscular dystrophy phenotype
The DMD pathogenesis is partially explained by the lack of
the signaling role of dystrophin, which normally localizes
nNOS to the sarcolemma through binding to the C-
terminal region of dystrophin [6]. The nNOS is responsible
for NO production to facilitate smooth muscle vasodila-
tion in response to increased metabolic demands. During
muscle contraction, NO-mediated vasodilation is import-
ant to help offset the α-adrenergic vasoconstriction in re-
sponse to sympathetic activation, which optimizes muscle
perfusion [18]. This functional response is intact in healthy
children, but in children with DMD the sympathetic vaso-
constriction in skeletal muscle is unopposed due to lack of
NO-mediated vasodilation [18].
The nNOS is absent from the sarcolemma and is
greatly downregulated in the cytoplasm of dystrophin-
deficient muscle, which results in muscle vasoconstric-
tion and abnormal blood flow during skeletal muscle
contraction [6,18,19]. Specifically, loss of dystrophin in
the smooth muscle results in a decreased capacity of
the vasculature to respond to shear stress induced
endothelium-dependent dilation, probably related to the
signaling defects seen in both force transduction and
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at the endothelial cell surface is a known catalyst for
angiogenesis [20-23], so new blood vessel formation could
be downregulated and mismatched to metabolic need in
the absence of dystrophin due to defects in mechano-
transduction. Lack of the signaling and structural roles
of dystrophin in DMD pathogenesis have led to a two-
hit hypothesis, whereby the combination of functional
ischemia due to reduced capacity to benefit from NO-
mediated protection and an increased susceptibility to
metabolic stress are both required to cause myocyte da-
mage (Figure 1A) [17]. So although not completely culpable
for the observed pathogenesis, impaired vascular function-
ing seems to be both inherent to DMD and an accelerant
to tissue damage in the skeletal and cardiac muscles.
Recent studies suggest that the two-hit hypothesis
should migrate away from simply observational specula-
tion towards a more widely accepted, evidence-based
DMD pathogenic theory. One functional study using
model DMD mdx mice showed quantitative evidence
supporting the two-hit hypothesis, where inhibition of
NO/EDHF (EDHF is endothelium-derived hyperpolariz-
ing factor, another vasodilator) alone in wild-type mice
caused similar functional ischemia (one-hit) to that seen
in mdx mice [24]. But, the forced functional ischemia
alone in the wild-type mice did not induce similar levels
of muscle cell death seen in mdx mice [24]. Two-hits,
consisting of severe ischemia and strenuous tetanic stim-
uli, were necessary to produce the same contraction-
dependent myofiber damage in wild-type mice to that of
mdx mice [24]. So, mdx myofibers exhibit enhanced
vulnerability to metabolic and mechanical stress inde-
pendently of the altered vasodilatory response, yet the
combinatory effect of both factors (two-hits) is necessary
to mediate the cell death numbers seen in mdx myo-
fibers. This could also explain why nNOS knockout mice,
a one-hit model, do not develop muscular dystrophy, yet
myocardial specific nNOS expression prevents cardiomy-
opathy in mdx mice by increasing the capacity to benefit
from NO-mediated protection [25,26]. Interestingly, mdx
mice that only express dystrophin in smooth muscle
(SMTg/mdx), which has a prominent role in regulation of
vascular tone and blood flow, have an intermediate
phenotype between wild-type and mdx mice [27]. The
SMTg/mdx mice showed some, albeit not total, recovery
of the NO-dependent vasorelaxation mechanism in ac-
tive skeletal muscle [27]. In the SMTg/mdx model, lack
of dystrophin at the myofiber level and the consequent
lack of complete force mechanotransduction in response
to functional demands were perhaps partially responsible
for the insufficient phenotypic recovery. These data over-
whelmingly reveal the important role the vasculature
plays in DMD pathogenesis and highlight a novel arena
for therapeutic intervention.Improved vasorelaxation capacity
Angiotensin-converting enzyme inhibitors
The renin-angiotensin-aldosterone system plays a vital
role in regulating both systemic vascular resistance and
total blood volume, which together impact arterial pres-
sure and myocardial function. A key component is the
angiotensin-converting enzyme (ACE), which transforms
the peptide hormone angiotensin I into angiotensin II; cir-
culating angiotensin II then stimulates vascular smooth
muscle contraction, increasing vascular resistance and ar-
terial pressure. Angiotensin II also induces the release of
aldosterone, which increases sodium and water retention,
and vasopressin, which increases water retention.
Preventing angiotensin II production through pharmaco-
logical ACE inhibition has been shown to reduce high
blood pressure and cardiac workload through enhanced
vasorelaxation and prevention of downstream hormone
release, and ACE inhibitors (ACEIs) are currently used to
treat congestive heart failure and hypertension [28-30]. As
such, improving cardiac function and enhancing systemic
vasorelaxation capacity through ACE inhibition in DMD
patients could have prophylactic benefit by mitigating the
functional ischemia and consequently diminishing myo-
necrosis. In mdx mice, the ACEI captopril administered
over an 8-week period and prior to the onset of cardio-
myopathy was shown to reduce cardiac afterload,
increase myocardial contractility, and improve cardiac
hemodynamics compared to mdx control mice [31]. In
clinical studies, administration of the ACEI perindopril
has shown that early treatment in 9.5- to 13-year-old
DMD patients with normal cardiac functioning (as mea-
sured by normal left ventricular ejection fraction or LVEF),
is capable of delaying both the onset and progression of
left ventricular dysfunction and significantly lowering
mortality rates compared to patients starting treatment 3
years later [32,33]. Results are less clear in DMD cases in-
volving established cardiomyopathy where administration
of the ACEI enalapril showed functional normalization in
just 43% of cases, but this positive functional effect was
maintained by most subjects for up to four years [34].
Combination therapy using ACEIs and β-adrenergic
receptor antagonists or β-blockers (BBs) has also been
investigated for use in DMD treatment. Catecholamines
increase heart rate and myocardial contractility through
the β-adrenergic receptors, and thus targeted BBs cause
the heart to beat slower and with less force and are typ-
ically given to patients with arrhythmia or disordered
automaticity. One study that utilized a combination of
BBs and ACEIs in DMD patients with established cardio-
myopathy found a positive effect on long-term survival,
especially for individuals that showed no overt symptoms
of heart failure despite documented left ventricular dys-
function [35]. A more recent study also investigated DMD
patients with established cardiomyopathy but broke
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ACEI plus BB (metoprolol) [36]. Both treatment groups
displayed improvements in cardiac function compared to
pre-therapy measurements, but no significant difference
in cardiac function was seen between groups [36]. Future
studies should address treatment using ACEI alone or
ACEI plus BB in DMD cases where cardiomyopathy has
not been fully established to assess the potential for
prophylactic benefit as this could definitively rule out the
need for a BB. Additionally, with regard to the two-hit hy-
pothesis, studies that address functional ischemia attenu-
ation to mitigate myonecrosis through enhanced tissue
perfusion by ACEI-mediated vasorelaxation have not yet
been performed.
Another therapeutic strategy that targets the renin-
angiotensin-aldosterone system to improve vasorelax-
ation capacity utilizes the antihypertensive drug losartan,
which is an angiotensin II type I receptor antagonist or
angiotensin receptor blocker (ARB). Long-term adminis-
tration of losartan in mdx mice showed improvements
in myocardial function, but not skeletal muscle function,
and reductions in mortality compared to control [37,38].
Explanations as to why losartan could only ameliorate
the function of cardiac muscle remain limited, but the
primary mechanism could be the significant reduction in
afterload seen in the hearts of losartan treated mdx mice
[38]. Decreased afterload certainly reduces cardiac work-
load, and this may minimize mechanical injury and sub-
sequent fibrosis to the sensitive cardiomyocytes in mdx
hearts. Still, the use of losartan as a prophylactic treatment
against DMD-related cardiomyopathy seems promising
based on these pre-clinical studies and the current clinical
availability of losartan (COZAAR™) for its use in hyper-
tension. Future investigation should be directed at evaluat-
ing losartan in DMD patients but also, owing to pathway
similarity, at comparing the effectiveness of losartan to the
many FDA-approved ACEIs.
The definitive mechanism behind reducing cardiomyop-
athy via ARBs, ACEIs, and/or BBs in DMD patients is not
completely established, but reduced aldosterone signaling
through ACE inhibition could prevent fibrotic tissue
development, as previous use of aldosterone-specific
blockers has shown benefit in cases of heart failure
[39-42]. Additionally, angiotensin II can directly induce
vasoconstriction, pro-fibrotic Smad signaling, pro-fibrotic
transforming growth factor beta (TGF-β) production, and
the ubiquitin-proteasome pathway that has a role in the
proteolysis happening in dystrophic tissues [43-46].
Angiotensin II is also known to enhance NADPH-oxidase
activity, which leads to overproduction of superoxide
anion and accounts for the oxidative stress in cardiac and
skeletal muscle of the mdx mouse [47-52]. ACE inhibition
can reduce these adverse effects, and a study with mdx
mice demonstrated that the ACEI enalapril can preventangiotensin II dependent stimulation of pro-oxidant and
pro-inflammatory pathways [53]. Overall, ACEIs and/or
BBs appear to be excellent candidates for DMD therapy
based on current clinical availability and demonstrated
ability to reduce many of the negative outcomes normally
associated with the DMD pathogenic process. Still, a
broader investigation regarding the potential prophylactic
benefit of ACEIs should be conducted to determine an op-
timal age of initiation.
Phosphodiesterase 5 inhibitors
In the NO-cGMP signaling pathway, nitric oxide synthase
(NOS) produces NO to activate soluble guanylyl cyclase
(sGC) to synthesize cyclic guanosine monophosphate
(cGMP), and cGMP activates protein kinase G to induce
vasodilation. The cGMP-specific phosphodiesterases are
responsible for cGMP degradation, so vasoconstriction be-
gins as concentrations of cGMP diminish. This pathway is
disrupted in dystrophin deficient membranes, as nNOS is
absent from the sarcolemma and greatly downregulated,
which contributes to the observed functional ischemia
[6,19]. Additionally, studies have shown greater cGMP-
specific phosphodiesterase 5 (PDE5) activity in mdx skel-
etal muscle samples and decreased cGMP production
compared with controls [54,55]. Recently, cGMP-specific
PDE5 inhibitors, specifically tadalafil (Cialis™ or Adcirca™)
and sildenafil (Viagra™ or Revatio™) have been investi-
gated for their potential in ameliorating the functional is-
chemia in DMD by increasing intracellular levels of cGMP
to prolong vasodilation and increase blood flow to tissues.
Asai et al. elegantly showed that tadalafil administra-
tion prior to progressive myofiber damage was able to
significantly lower the net quantity of myofiber damage
in mdx mice compared to placebo [24]. Essentially, at-
tenuation of functional ischemia using tadalafil was
shown to reduce the extent of contraction-induced dam-
age [24]. Additionally, early treatment utilizing PDE5
inhibitors could have clinical prophylactic benefit, for
mdx mice treated with tadalafil from conception showed
improved histology [24]. Khairallah et al. showed that car-
diac mRNA expression levels of atrial natriuretic factor
(ANF), an early indicator for initiation of cardiomyopathic
remodeling, was significantly reduced in mdx mice treated
with sildenafil [56,57]. This implies that sildenafil is cap-
able of inhibiting the advancement of cardiomyopathic
remodeling at early stages of DMD [57]. Sildenafil has also
been shown to have positive functional effects in the
hearts of mdx mice, notably by avoidance of cardio-
myocyte damage produced in vivo via cardiac workload
augmentation and maintenance of an elevated heart rate
response for a significantly longer period of time com-
pared with placebo [57]. Interestingly, administration of
sildenafil is even capable of reversing cardiac dysfunction
in mdx mice with established cardiomyopathy [58].
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reversal are still unclear.
Additionally, PDE5 inhibitors have also shown im-
provement in muscle tissue from other vertebrate models
of DMD, namely two dystrophin deficient zebrafish
models known as sapje and sapje-like mutants [59,60].
Dystrophin-null zebrafish treated with aminophylline, a
nonselective phosphodiesterase inhibitor, were able to
survive significantly longer compared to controls and
had restored skeletal muscle structure similar to wild-
type zebrafish [61]. Furthermore, analysis of sapje mu-
tants treated 1 to 4 days postfertilization with different
phosphodiesterase inhibitors revealed that treatment with
aminophylline or sildenafil citrate resulted in the lowest
percentage of fish showing abnormal muscle structure
[61]. These data suggest that aminophylline and sildenafil
citrate are capable of preventing the onset of aberrant
muscle architecture in dystrophin-null zebrafish. These
findings from DMD model zebrafish are analogous to the
results seen from mdx mice treated with PDE5 inhibitors,
and the consistency of these results across several DMD
models leaves hope that these compounds could benefit
individuals living with DMD. Clinical trials assessing
PDE5 inhibitors for DMD patients are currently under-
way, and future use of tadalafil or sildenafil for these indi-
viduals seems promising based on preclinical studies and
current clinical availability of these drugs for their use in
treating erectile dysfunction and pulmonary hypertension.
Increased vascular density
Vascular endothelial growth factor administration
The central paradigm behind the previously discussed
PDE5 and ACEI therapies for DMD was that increasing
the vasorelaxation capacity of the vasculature would be
able to increase perfusion, diminish the effects from
functional ischemia, and decrease myocyte damage. How-
ever, another technique to increase tissue perfusion would
be to increase the density of the underlying vascular archi-
tecture that nourishes the skeletal and cardiac muscles.
One method of increasing vascular density is to augment
angiogenesis, which regulates the production of new
vasculatures from the existing framework. The vascular
endothelial growth factor (VEGF) family of signal glyco-
proteins acts as potent promoters of angiogenesis during
embryogenesis and postnatal growth. Specifically, the
binding of the VEGF-A ligand with the VEGF receptors
has been shown to promote vascular permeability and also
trigger endothelial cell migration, proliferation, and sur-
vival, and the newly formed endothelial cells provide the
basic structure of new vasculatures [62]. The dominant
VEGF signal molecule for angiogenesis, VEGF-A, mediates
its signal through VEGF receptor-1 (VEGFR-1, hereafter
Flt-1) and VEGF receptor-2 (VEGFR-2, hereafter Flk-1)
[63]. A soluble form of Flt-1 (sFlt-1) also exists, but lacksan intracellular signaling domain and thus only serves in a
regulatory capacity by sequestering VEGF-A [63]. Flt-1
and Flk-1 contain an extracellular VEGF-A-binding do-
main and an intracellular tyrosine kinase domain, and
both show expression during the developmental stage and
tissue regeneration in hemangioblasts and endothelial cell
lineages [63-65]. Flt-1 has a 10 times greater binding affin-
ity for VEGF-A (Kd approximately 2 to 10 pM) compared
to Flk-1, but the weaker tyrosine kinase domain indicates
that angiogenic signal transduction following VEGF-A
binding to Flt-1 is comparably weaker than the Flk-1 sig-
nal (Figure 2A) [63]. As such, homozygous Flt-1 gene
knockout mice die in the embryonic stage from endothe-
lial cell overproduction and blood vessel disorganization
(Figure 2B) [64-66]. Inversely, homozygous Flk-1 gene
knockout mice die from defects in the development of or-
ganized blood vessels due to lack of yolk-sac blood island
formation during embryogenesis (Figure 2C) [67]. Both
the Flt-1 and Flk-1 receptors are needed for normal devel-
opment, but selective augmentation in VEGF-A concen-
tration should allow for greater binding to the Flk-1
receptor and induce a pro-angiogenic effect that increases
capillary density.
Several studies have demonstrated that administration of
VEGF using exogenous expression mediated through
engineered myoblasts, direct systemic injections, or adeno-
associated viral (AAV) vectors are capable of initiating an
angiogenic signal in the myocardium and skeletal muscle
in both ischemic and non-ischemic conditions [69-72].
However, these same studies do highlight the importance
of precisely regulating VEGF delivery quantities for future
clinical use, as overadministration has been shown to have
deleterious effects in animal models, such as hemangioma
formation [70]. Unfortunately, and to the best of our
knowledge, functional studies that assess blood flow in
DMD model organisms following VEGF-induced angio-
genesis have not yet been conducted. However, one study
found that four weeks following intramuscular adminis-
tration of rAAV-VEGF vectors in the bicep and tibialis
anterior (TA) muscles of 4-week-old mdx mice, the
rAAV-VEGF-treated mdx mice showed significantly
greater forelimb strength compared to pretreatment
levels and AAV-LacZ-treated control mdx mice [73]. The
same study confirmed the feasibility of VEGF-mediated
angiogenic induction in mdx mice and showed greater
capillary density, particularly in the area of regenerating
fibers, as well as reduced necrotic fiber area in biceps
muscle compared to AAV-LacZ-treated control mdx
mice [73]. So, although this study did not directly assess
reduction of functional ischemia via enhanced vascular
density through VEGF-induced angiogenesis, it was able
to demonstrate similar outcomes from the PDE5 inhibi-
tor studies, especially the decrease seen in necrotic fiber
































Figure 2 Flt-1 is a decoy receptor for vascular endothelial growth factor (VEGF) pro-angiogenic signaling. (A) In the wild-type scenario,
VEGF induces a pro-angiogenic signal by binding the Flt-1 or Flk-1 receptors [63]. Flt-1 has a higher binding affinity for VEGF but transmits a
weaker angiogenic signal compared to Flk-1, which implies that Flt-1 acts a negative regulator of angiogenesis [63]. The soluble form of Flt-1
(sFlt-1) lacks the transmembrane and intracellular signaling domains of Flt-1 and only serves a regulatory role by sequestering VEGF [63]. (B) Flt-1
homozygous knockout (Flt-1−/−) mice die in the early embryonic stage from endothelial cell overproduction and blood vessel disorganization,
indicating that Flt-1 is a decoy regulator for endothelial growth/differentiation [64-66]. (C) Flk-1 homozygous knockout (Flk-1−/−) mice die in the
early embryonic stage from defects in the development of organized blood vessels, indicating that Flk-1 is a positive regulator for endothelial
growth/differentiation [67]. (D) Developmental reduction of the Flt-1 receptor through haploinsufficiency of the Flt-1 gene (Flt-1+/−) has been
shown to increase capillary density in skeletal muscle, and this same phenomenon has been demonstrated in mdx mice (mdx:Flt-1+/−) [79]. The
mdx:Flt-1+/− mice also showed improved histological and functional parameters normally associated with the Duchenne muscular dystrophy
(DMD) pathology [68].
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VEGF delivery also has a powerful pro-myogenic effect.
In normal skeletal muscle tissues, VEGF administration
induces muscle fiber regeneration and promotes muscle
recovery after ischemic and chemical damage [74]. In
in vitro studies using C2C12 myoblast cell line and pri-
mary mouse myoblasts derived from cultured SCs, VEGF
was shown to promote growth and protect cells from
apoptosis [74]. Similar effects have been documented
in dystrophin deficient muscle tissues, where rAAV-
VEGF-treated mdx mice showed an increase in the area
occupied by regenerating fibers and an increased number
of activated SCs and developmental myosin-heavy chain-
positive fibers in skeletal muscles [73]. In vivo transplant-
ation of muscle-derived stem cells (MDSCs) engineered to
overexpress VEGF into dystrophic skeletal muscle results
in an increase in angiogenesis and endogenous muscle re-
generation along with reduction in fibrosis both two and
four weeks following transplantation [75]. Thus, the dual
functionalities of VEGF, especially the pro-angiogenic andpro-myogenic effects, are capable of improving both the
histological and functional parameters normally associated
with mdx muscle pathophysiology.
These data seem logical because developmentally redu-
cing angiogenesis in mdx mice through ablation of matrix
metalloproteinase-2 impairs the growth of regenerated
myofibers and decreases VEGF expression, further com-
plementing current theories about the close developmen-
tal relationship between angiogenesis and myogenesis
[76]. But what is the pro-myogenic mechanism of VEGF
delivery? SCs are clearly the dominant muscle-specific
stem cells utilized for muscle growth, repair, and regener-
ation, and the number of SCs parallels muscle capillary
quantity, largely because SCs reside in a juxtavascular
niche [77,78]. In fact, most SCs maintain tight locality to
capillaries regardless of character, including quiescent SCs,
proliferating SCs (myogenic precursor cells), and differen-
tiating SCs (myocytes), and differentiating myogenin-
positive myocytes assessed from DMD muscle biopsies
show spatiotemporal association with new capillary
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that endothelial cells augment myogenic precursor cell
growth while differentiating SCs display pro-angiogenic
characteristics, thus demonstrating a complementary
angio-myogenesis signaling system [78]. Specifically, VEGF
stimulated in vitro myogenic precursor cell growth, which
supports the notion that VEGF is a co-regulatory substance
for both angiogenesis and myogenesis [78,79]. Recent work
demonstrates that myofibers, SCs or myogenic precursor
cells are negative for both Flt-1 and Flk-1, indicating that
the effects of VEGF on these cells may be mediated
through other VEGF receptors, such as neuropilin-1
(NRP1) and neuropilin-2 (NRP2) [68]. NRP1 and NRP2
can bind to VEGF with a high affinity and act as co-
receptors for Flk-1 and Flt-3, respectively [80]. However,
other studies have shown that in some developmental
cases, the cellular proliferation functions of VEGF via
binding to NRP1 are independent of Flk-1 [81]. Thus, the
exact mechanism of Flt-1/Flk-1 independent VEGF sig-
naling remains to be elucidated.
An additional element of pro-angiogenic induction is
that the expansion of the juxtavascular niche of SCs also
serves to increase the basal number of SCs, and this is
something not seen in the previously described vasorelax-
ation strategies [68]. Normally, the successive rounds of
regeneration and degeneration seen in mdx tissue serves
to exhaust the SC pool and reduce the regenerative cap-
acity of the muscle tissue, which decreases SC quantity
over time [82,83]. This predetermined decline can be
attenuated by improving the regenerative capacity of the
muscle through an increase in the number of SCs present,
which can be accomplished through expansion of the SC
juxtavascular niche, including microcapillaries [78,84,85].
As for the future of VEGF therapies in DMD patients,
more data is certainly needed before clinical benefit can
be realized. Most important is deciphering effective dos-
ing levels and delivery vehicles, which are both extraor-
dinarily difficult owing to the fact that the body of
pharmacology knowledge has shown us that inhibition is
easier than introduction. Similarly, there is no agreed
upon clinical standard for what constitutes a therapeutic
or pathologic increase in the density of the vasculatures.
Also, growth factors like VEGF need to be closely mo-
nitored due to carcinogenic properties. Similar to the
PDE5 inhibitor studies, the effects of VEGF-induced
angiogenesis to enhance capillary quantity and mitigate
contraction-induced muscle damage via functional ische-
mia reduction should be further investigated to validate
this hypothesis. Moreover, data regarding the functional
aspects of the myocardium in dystrophin deficient tissues,
the developmental effects of earlier VEGF administration,
and the basal quantity of SCs following VEGF-induced
angiogenesis in organisms lacking dystrophin all could
help ready this therapy for clinical trials in DMD patients.VEGF receptor regulation
A different pro-angiogenic approach that also increases
vascular density to ameliorate the functional ischemia in
DMD would be to modulate the VEGF receptors. As
previously described, Flt-1 acts as a decoy receptor and
modulates angiogenesis through its ability to sequester
VEGF-A, which reduces signaling through Flk-1. So, al-
though both Flt-1 and Flk-1 are inherently pro-angiogenic,
due to the high affinity and low tyrosine kinase activity of
Flt-1 over Flk-1 with respect to VEGF-A, Flt-1 acts as a
VEGF-A sink preventing Flk-1 access to VEGF-A and
thereby functioning as a negative regulator of angiogen-
esis. This phenomenon has been previously discussed in
more detail, and it implies that reduced levels of Flt-1
and/or sFlt-1 could increase the serum concentration of
free VEGF-A available to bind Flk-1 and induce a pro-
angiogenic response [86].
Interestingly, Flt-1 reduction through haploinsufficiency
of Flt-1 (Flt-1+/−) produced increased capillary density
in skeletal and cardiac muscle compared with control
(Flt-1+/+) in a murine model (Figure 2D) [68]. More sig-
nificant to this discussion, developmentally reducing Flt-1
through the same genetic method was also shown to
further enhance capillary density in the skeletal muscle
of mdx mice (mdx:Flt-1+/−) compared to controls (mdx:
Flt-1+/+) [68]. The increased capillary density seen in mdx:
Flt-1+/− mice serve as a proof of concept that regulating
VEGF-A receptors can stimulate a similar pro-angiogenic
effect to that seen with direct VEGF-A administration in
dystrophin-deficient organisms. More importantly, the
changes seen in the mdx:Flt-1+/− mice persist into adult-
hood, yet it remains unclear if this effect must be initiated
during developmental stages or if it can be recapitulated in
postnatal models.
Analysis of the mdx:Flt-1+/− mice with increased capil-
lary density demonstrated improved skeletal muscle hist-
ology with a reduction in both myocyte damage and
fibers with centrally located nuclei, which strongly sug-
gests that mdx:Flt-1+/− fibers display less fiber turnover
compared to the mdx:Flt-1+/+ controls [68]. Addition-
ally, mdx:Flt-1+/− fibers show less calcification, fibrosis,
and membrane permeability, all of which are downstream
effects of dystrophin deficiency [68]. These histological
improvements also translated to improved functional pa-
rameters such that increased capillary density resulted in
increased muscle tissue perfusion and improved skeletal
muscle contractile function [68]. Furthermore, Flt-1 has
also been assessed in another DMD mouse model: mdx:
utrophin (utrn)−/− mice. These mice, deficient for both
dystrophin and the dystrophin-related protein utrophin,
display a more severe, progressive form of muscular dys-
trophy as compared with the mdx mice [87,88]. Long term
studies using the mdx:utrn−/−:Flt-1+/− mice with increased
capillary density showed significant increases in body mass
Table 1 Summary of vascular targeted therapies for Duchenne muscular dystrophy
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mice [68].
Absolute mechanisms that explain the improved
phenotype and survival seen in mdx:Flt-1+/− mice and
mdx:utrn−/−:Flt-1+/− mice remain to be elucidated. But
owing to pathway similarity, the explanation is probably
similar to descriptions of VEGF-induced angiogenesis in
mdx mice, namely the close developmental relationship
between myogenesis and angiogenesis. Increasing tissue
perfusion may compensate for lack of NO-mediated
vasodilation, which would attenuate one of the proposed
‘two-hits’ required for myocyte damage. Another theory
behind the progressive nature of the DMD pathology is
the SC exhaustion model [83]. This theory states that
easily damaged DMD myofibers are constantly replaced
by endogenous SCs, yet the constant SC cycling leads
to rapid shortening of telomerase length and eventual
exhaustion of the SC pool [82,83]. Interestingly, mdx:
Flt-1+/− were shown to have developmentally increased
numbers of SCs, perhaps mediated through an expanded
SC vascular niche. Thus, enhancement in the basal num-
ber of SCs could mitigate the accelerated age-related de-
cline seen among SCs from dystrophin-deficient muscle
tissue [13].
Overall, Flt-1 is a novel target for pro-angiogenic ther-
apy in DMD. Greater blood perfusion alone seems to
compensate for the functional ischemic phenotype in
mdx mice, but definitive studies showing attenuation of
functional ischemia through Flt-1 signal mitigation to re-
duce the effects of contraction induced damage have not
been shown. Flt-1 has also been investigated for its role
in cancer where it acts as a positive regulator of the
pathological angiogenesis seen with tumor formation
[89], which opposes the physiological role of Flt-1 as a
negative angiogenic regulator. Thus, numerous small
molecules have already been investigated and verified
(in vivo and in vitro) that can antagonize Flt-1 binding
to VEGF, reduce angiogenesis, and prevent tumor
growth [90]. These same small molecules could be used
to selectively block Flt-1 function and promote angio-
genesis in dystrophin-deficient tissue. Still, more screen-
ing studies could be needed to decipher substances that
are viable in vivo and can reduce Flt-1 function in order
to fully translate the results seen from the developmental
studies with mdx:Flt-1+/− and mdx:utrn−/−:Flt-1+/− mice
using a pharmaceutical agent.
Conclusions
The role of the vasculature in DMD can no longer be ig-
nored in light of the mounting evidence for its role in the
pathogenic process. With this new knowledge in mind and
with the dearth of current treatments, this review focused
on a variety of new therapeutic options that specifically tar-
get these DMD vascular defects, namely attenuation of thefunctional ischemia (see Table 1 for summary of therapies).
One therapy improves systemic vasorelaxation capacity
using ACEIs with or without BBs, and this method has
shown clinical utility in both preventing and improving the
adverse cardiac events normally associated with the DMD
phenotype. Treatment using PDE5 inhibitors also improves
systemic vasorelaxation capacity, and preclinical evidence
from DMD murine models demonstrates the ability of
PDE5 inhibitors to prevent skeletal and cardiac muscle
damage and even reverse the functional parameters associ-
ated with established cardiomyopathy. Both PDE5 and
ACEI therapies have a clear practical advantage as they
have extensive clinical safety records and many of the
drugs are clinically available. There are a wide variety of
ACEIs that are FDA approved to treat heart failure and
hypertension, including benazepril (Lotensin™), captopril
(Capoten™), enalapril (Vasotec™), fosinopril (Monopril™),
lisinopril (Prinivil™, Zestril™) moexipril (Univasc™), perin-
dopril (Aceon™), quinapril (Accupril™), ramipril
(Altace™), and trandolapril (Mavik™). There are also sev-
eral PDE5 inhibitors that received FDA approval for
treating erectile dysfunction or hypertension, including
tadalafil (Cialis™ or Adcirca™), sildenafil (Viagra™ or
Revatio™), and vardenafil (Levitra™ or STAXYN™). Add-
itionally, sildenafil has already been extensively studied in
a pediatric population and was found to be safe for pul-
monary hypertension treatment [91]. Both tadalafil and
sildenafil are currently in a phase 1 clinical trial
(NCT01580501) that will assess these drugs ability to at-
tenuate functional ischemia in boys with DMD, and other
future clinical studies could address the ability of ACEIs to
mitigate the same effect.
Therapies that enhance the underlying vascular archi-
tecture through pro-angiogenic induction include VEGF
administration and also VEGF receptor modulation. The
pro-angiogenic therapies have shown exciting preclinical
proof of concept evidence in DMD murine models, espe-
cially the expansion in the basal number of SCs mediated
through a larger juxtavascular SC niche and the docu-
mented pro-myogenic effects. Still, the pro-angiogenic
strategies are in early stages and both methods need de-
finitive means of achieving their desired result and more
safety information before clinical trial initiation. In all, the
hope is that at least some or combinations of these
vascular-targeted therapies will soon have clinical utility
and provide current and future human beings living with
DMD enhanced control over their own destiny.
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